Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Primaquine phosphate
Drug ID BADD_D01839
Description An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
Indications and Usage For the treatment of malaria.
Marketing Status approved
ATC Code P01BA03
DrugBank ID DB01087
KEGG ID D02126
MeSH ID D011319
PubChem ID 6135
TTD Drug ID D0T1LK
NDC Product Code 76385-102; 14096-177; 0024-1596; 60429-035; 65392-2502; 50742-191; 42973-177; 73309-012; 42291-510; 43063-225; 43063-721; 57451-1198
UNII H0982HF78B
Synonyms Primaquine | Primaquine Phosphate | Phosphate, Primaquine | Primacin | Primaquine Diphosphate | Diphosphate, Primaquine
Chemical Information
Molecular Formula C15H27N3O9P2
CAS Registry Number 63-45-6
SMILES CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2.OP(=O)(O)O.OP(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Arrhythmia02.03.02.001---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dyspepsia07.01.02.001--
Electrocardiogram QT prolonged13.14.05.004--
Haemolytic anaemia01.06.03.002---
Leukopenia01.02.02.001---
Methaemoglobinaemia01.05.01.002--
Nausea07.01.07.001--
Pruritus23.03.12.001--
Rash23.03.13.001---
Vomiting07.01.07.003--
The 1th Page    1    Total 1 Pages